| Literature DB >> 21994538 |
Patrick C Y Woo1,2,3, Susanna K P Lau1,2,3, Cyril C Y Yip3, Yi Huang3, Kwok-Yung Yuen1,2,3.
Abstract
After human coronaviruses OC43, 229E and NL63, human coronavirus HKU1 (HCoV-HKU1) is the fourth human coronavirus discovered. HCoV-HKU1 is a group 2a coronavirus that is still not cultivable. The G + C contents of HCoV-HKU1 genomes are 32%, the lowest among all known coronaviruses with complete genome sequences available. Among all coronaviruses, HCoV-HKU1 shows the most extreme codon usage bias, attributed most importantly to severe cytosine deamination. All HCoV-HKU1 genomes contain unique tandem copies of a 30-base acidic tandem repeat of unknown function at the N-terminus of nsp3 inside the acidic domain upstream of papain-like protease 1. Three genotypes, A, B and C, of HCoV-HKU1 and homologous recombination among their genomes, are observed. The incidence of HCoV-HKU1 infections is the highest in winter. Similar to other human coronaviruses, HCoV-HKU1 infections have been reported globally, with a median (range) incidence of 0.9 (0 - 4.4) %. HCoV-HKU1 is associated with both upper and lower respiratory tract infections that are mostly self-limiting. The most common method for diagnosing HCoV-HKU1 infection is RT-PCR or real-time RT-PCR using RNA extracted from respiratory tract samples such as nasopharyngeal aspirates (NPA). Both the pol and nucleocapsid genes have been used as the targets for amplification. Monoclonal antibodies have been generated for direct antigen detection in NPA. For antibody detection, Escherichia coli BL21 and baculovirus-expressed recombinant nucleocapsid of HCoV-HKU1 have been used for IgG and IgM detection in sera of patients and normal individuals, using Western blot and enzyme-linked immunoassay.Entities:
Keywords: HKU1; coronavirus; human; novel
Year: 2009 PMID: 21994538 PMCID: PMC3185465 DOI: 10.3390/v1010057
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Figure 1.Phylogenetic analysis of RNA-dependent RNA polymerases of coronaviruses with complete genome sequences available by the end of 2008. The tree was constructed by neighbor joining method using Kimura's two-parameter correction and bootstrap values calculated from 1000 trees. Nine hundred and fifty eight amino acid positions were included in the analysis. The scale bar indicates the estimated number of substitutions per 50 amino acids.
HCoV-229E, human coronavirus 229E (NC_002645); PEDV, porcine epidemic diarrhea virus (NC_003436); TGEV, porcine transmissible gastroenteritis virus (NC_002306); FCoV, feline coronavirus (AY994055); PRCV, porcine respiratory coronavirus (DQ811787); HCoV-NL63, human coronavirus NL63 (NC_005831); bat-CoV-HKU2 (EF203064), HKU4 (NC_009019), HKU5 (NC_009020), HKU8 (NC_010438), HKU9 (NC_009021), 1A (NC_010437), 1B (NC_010436), 512/2005 (NC_009657); HCoV-HKU1, human coronavirus HKU1 (NC_006577), HCoV-OC43, human coronavirus OC43 (NC_005147); MHV, mouse hepatitis virus (NC_006852); BCoV, bovine coronavirus (NC_003045); PHEV, porcine hemagglutinating encephalomyelitis virus (NC_007732); ECoV, equine coronavirus (NC_010327); SARS-CoV, SARS coronavirus (NC_004718); bat-SARS-CoV-HKU3, bat-SARS coronavirus HKU3 (NC_009694); IBV, infectious bronchitis virus (NC_001451); TCoV, turkey coronavirus (NC_010800); SW1, beluga whale coronavirus (NC_010646); BuCoV-HKU11, Bulbul coronavirus HKU11 (NC_011548); ThCoV-HKU12, Thrush coronavirus HKU12 (NC_011549); MuCoV-HKU13, Munia coronavirus HKU13 (NC_011550).
Figure 2.Genome organization of HCoV-HKU1. Predicted ORF 1ab, encoding the nonstructural polyproteins (nsp1 to nsp16) and ORFs encoding the HE, S, E, M and N structural proteins are indicated. Arrows indicate putative cleavage sites (with the corresponding nucleotide positions) of the replicase polyprotein encoded by ORF 1ab (amino acids at boundaries also shown) and S protein. Putative positions of TRS are marked by▪. Major parts of ORF 1ab (PL1pro, PL2pro, 3CLpro, pol and helicase) encoding key enzymatic activities are colored in yellow. ATR represents the acidic tandem repeat in nsp3.
Clinical studies on HCoV-HKU1
| 1 | [ | Hong Kong | 418 patients | Hospitalized patients with community-acquired pneumonia | 12 months (Mar 2003 – Mar 2004) | 10 (2.4) | 8 (80) | Not performed | Not performed | Not performed | 2 died |
| 2 | [ | Australia | 324 specimens | Children presented to Queensland hospitals or general practitioners with acute respiratory tract infections | 4 months (May 2004 – Aug 2004) | 10 (3.1) | Not mentioned | 11 (3.4) | 1 (0.3) | 0 (0) | Not mentioned |
| 3 | [ | France | 135 patients | Hospitalized patients with respiratory symptoms | 2 months (Feb 2005 – Mar 2005) | 6 (4.4) | 3 (50) | 2 (1.5) | 0 (0) | 2 (1.5) | Not mentioned |
| 4 | [ | USA | 1048 respiratory specimens from 851 children | Specimens from emergency department, inpatient wards, intensive care units, and hospital-affiliated primary care outpatient clinic | 12 months (Dec 2001 – Dec 2002) | 9 (1) patients | 5 (56) | Not performed | Not performed | Not performed | Not mentioned |
| 5 | [ | Hong Kong | 4181 specimens | Hospitalized patients with acute respiratory tract infections | 12 months (April 2004 – Mar 2005) | 13 (0.3) | 8 (62) | 53 (1.3) | 4 (0.1) | 17 (0.4) | All survived |
| 6 | [ | Switzerland | 540 specimens from 279 adults | Hospitalized patients with respiratory disease | 20 months | 4 (1.4) patients | Not mentioned | 12 (4.3) patients | 7 (2.5) patients | 6 (2.2) patients | Not mentioned |
| 7 | [ | Italy | 2060 children | Children who attended the emergency department with an acute disease excluding trauma | 5 months (Nov 2003 – Mar 2004) | 0 (0) | - | 17 (0.8) | 42 (2) | 20 (1) | - |
| 8 | [ | Italy | 227 children | Hospitalized children with acute respiratory infection or related conditions at the Pediatric Department | 12 months (Oct 2004 – Sep 2005) | 0 (0) | - | 6 (2.6) | 0 (0) | 1 (0.4) | - |
| 9 | [ | Italy | 685 specimens from 426 patients | Hospitalized patients with acute respiratory tract infections | 7 months (Nov 2005 – May 2006) | 10 (2.3) patients | 8 (80) | 8 (1.9) patients | 20 (4.7) patients | 11 (2.6) patients | Not mentioned |
| 10 | [ | Korea | 231 children | Hospitalized children with acute expiratory wheezing | 10 months (Feb 2006 – Nov 2006) | 0 (0) | - | 3 (1.3) | 2 (0.9) | 3 (1.3) | - |
| 11 | [ | Thailand | 734 patients | Patients hospitalized with pneumonia | Study year 1: Sep 2003 – Aug 2004 | 3 (0.4) | Not mentioned | 31 (4.2) | 3 (0.4) | 7 (1) 1 | Not mentioned |
| 1156 patients | Patients hospitalized with pneumonia | Study year 2: Sep 2004 – Oct 2005 | 9 (0.8) | 4 (0.4) | 7 (0.6) | (0.1) | |||||
| 513 patients | Outpatients with influenza-like illness | Study year 2: Sep 2004 – Oct 2005 | 1 (0.2) | 0 (0) | 2 (0.4) | 9 (1.8) | |||||
| 12 | [ | USA | 1043 children | Outpatients, emergency department patients and inpatients with acute respiratory illness | 12 months (Oct 2003 – Sep 2004) | 28 (2.7) | Not mentioned | 19 (1.8) | 8 (0.8) | 11 (1.1) | Not mentioned |
| 13 | [ | Switzerland | 112 infants | Infants followed prospectively during their first year of life for any respiratory or other disease symptoms and their treatment by weekly telephone interviews | 69 months (Apr 1999 – Dec 2004) | 1 (0.9) | Not mentioned | 7 (6.3) | 3 (2.7) | 9 (8) | Not mentioned |
| 14 | [ | France | 1002 specimens from 928 children | Hospitalized children with respiratory or general symptoms | 9 months (Sep 2004 – May 2005) | 38 (3.8) specimens | 8 (24) of 34 patients | 27 (2.9) specimens | 2 (0.2) specimens | 33 (3.6) specimens | All survived |
| 15 | [ | Jordan | 325 children | Children with acute respiratory infection admitted to the pediatric wards | 6 months (Dec 2003 – May 2004) | 0 (0) | - | Not performed | Not performed | 4 (1.2) | - |
| 16 | [ | Italy | 322 infants | Hospitalized infants with acute respiratory disease | 24 months (Oct 2004 – Sep 2006) | 6 (1.9) | Not mentioned | 11 (3.4) | 1 (0.3) | 10 (3.1) | Not mentioned |
| 17 | [ | Italy | 85 infants | Infants hospitalized for the first acute episode of wheezing | 6 months (Oct 2005 – Mar 2006) | 1 (1.2) | Not mentioned | 2 (2.4) | 0 (0) | 0 (0) | Not mentioned |
| 18 | [ | France | 159 specimens | Specimens collected from mother-child couples admitted in labor to the Gynecology-Obstetrics Unit | 18 months (Jul 2003 – Jun 2004 and Mar 2005 – Aug 2005) | 1 (0.6) | Not mentioned | 0 (0) | 11 (6.9) | 0 (0) | Not mentioned |
Gene targets and primer sequences for HCoV-HKU1 detection
| Studies | References | Place of study | Detection methods | Gene target | Target band size | Primer sequences |
|---|---|---|---|---|---|---|
| 1 | [ | Hong Kong | RT-PCR | 453 bp | Forward 5′-AAAGGATGTTGACAACCCTGTT-3′ | |
| 2 | [ | Australia | RT-PCR | 453 bp | Forward 5′-AAAGGATGTTGACAACCCTGTT-3′ | |
| 3 | [ | France | RT-PCR | N | 443 bp | Forward 5′-ACCAATCTGAGCGAAATTACCAAAC-3′ |
| 4 | [ | USA | RT-PCR | 440 bp | Forward 5′-GGTTGGGATTATCCTAAATGTGA-3′ | |
| 5 | [ | Hong Kong | RT-PCR | 453 bp | Forward 5′-AAAGGATGTTGACAACCCTGTT-3′ | |
| 6 | [ | Switzerland | Real-time | 506 bp | Forward 5′-GAATTTTGTTGTTCACATGGTGATAGA-3′ | |
| 7 | [ | Italy | Real-time | N | 64 bp | Forward 5′-AGTTCCCATTGCTTTCGGAGTA-3′ |
| 8 | [ | Italy | RT-PCR | 440 bp | Forward 5′-GGTTGGGACTATCCTAAGTGTGA-3′ | |
| 9 | [ | Italy | RT-PCR | N | 516 bp | Forward 5′-CAGTGTTTTGGTAAAAGAGGACC-3′ |
| 250 bp | Forward 5′-ACTCAAATGAATTTAAAATATGC-3′ | |||||
| 10 | [ | Korea | RT-PCR | 921 bp | Forward 5′-GTTCAAGTGTCGCTGTTCA-3′ | |
| 989 bp | Forward 5′-GGGTATGAAGTATCATCCTA-3′ | |||||
| 921 bp | Forward 5′-CATCTTATAAAGGATGTTGAC-3′ | |||||
| 11 | [ | Thailand | Real-time | 95 bp | Forward 5′-CCTTGCGAATGAATGTGCT-3′ | |
| 12 | [ | USA | Real-time | 96 bp | Forward 5′-TGGTGGCTGGGACGATATGT-3′ | |
| 13 | [ | Switzerland | Real-time | 506 bp | Forward 5′-GAATTTTGTTGTTCACATGGTGATAGA-3′ | |
| 14 | [ | France | RT-PCR | N | 439 bp | Forward 5′-ATCTGARCGAAAYYAYCAAAC-3′ |
| 15 | [ | Jordan | RT-PCR | 453 bp | Forward 5′-AAAGGATGTTGACAACCCTGTT-3′ | |
| 16 | [ | Italy | RT-PCR | 220bp | Forward 5′-TTATGGGTTGGGATTATCCYAARTGTGAT-3′ | |
| 214bp | Forward2 5′-ATGGGATGGGACTATCCTAAGTGTGATAGAG-3′ | |||||
| 17 | [ | Italy | RT-PCR | 440 bp | Forward 5′-GGTTGGGACTATCCTAAGTGTGA-3′ | |
| 18 | [ | France | Real-time | 96 bp | Forward 5′-TGGTGGCTGGGACGATATGT-3′ |